What are the recommended dosing regimens for doxepin in adults for insomnia and depression, including starting doses, titration steps, maximum doses, and adjustments for patients over 65 years or with hepatic impairment?

Doxepin Dosing

For insomnia in adults, start doxepin at 3-6 mg at bedtime; for depression, start at 75 mg daily and titrate to 75-150 mg daily, with elderly patients requiring lower starting doses of 25 mg or less.

Insomnia Dosing

Low-dose doxepin (3-6 mg) is specifically recommended for sleep maintenance insomnia 1. The American Academy of Sleep Medicine clinical practice guidelines suggest using doxepin as treatment for sleep maintenance insomnia based on trials of 3 mg and 6 mg doses 1.

Starting and Maintenance Doses for Insomnia:

• Standard adult dose: 3-6 mg at bedtime 2, 3
• Elderly patients (≥65 years): Start at 1-3 mg at bedtime 2
• Maximum studied dose: 6 mg for insomnia 1

The low-dose formulation works through selective H1-receptor antagonism and demonstrates efficacy after a single dose, with sustained benefit for up to 12 weeks without evidence of physical dependence or rebound insomnia upon withdrawal 3.

Depression Dosing

For depression, the FDA-approved dosing differs substantially from insomnia treatment 4:

Standard Adult Dosing:

• Starting dose: 75 mg daily 4
• Optimal range: 75-150 mg daily 4
• Severe illness: May increase gradually to 300 mg daily if necessary 4
• Maximum dose: 300 mg daily (additional benefit rarely obtained beyond this) 4
• Mild symptoms: 25-50 mg daily may suffice 4

Titration Strategy:

• Increase or decrease at appropriate intervals based on individual response 4
• Can be given as divided doses or once-daily (maximum 150 mg if once-daily) 4
• If once-daily dosing, give at bedtime 4
• Antidepressant effect may take 2-3 weeks to become evident 4

Special Populations

Elderly Patients (≥65 years):

Start at the low end of the dosing range 4:

• For insomnia: 1-3 mg at bedtime 2
• For depression: Start cautiously, typically at lower doses than standard adults 4
• Elderly patients are more prone to confusion, oversedation, and anticholinergic effects 4
• Observe closely for adverse effects 4

Hepatic Impairment:

• Reduce dose in patients with hepatic impairment 4
• Use caution and start at lower doses 4
• Specific dose adjustments not provided in FDA labeling, requiring clinical judgment

Renal Impairment:

• The extent of renal excretion has not been fully determined 4
• Exercise care in dose selection for patients with decreased renal function 4
• Start at lower doses and titrate cautiously

Critical Safety Considerations

Common Pitfalls:

• Do not confuse insomnia dosing (3-6 mg) with depression dosing (75-300 mg) - these are vastly different dose ranges for different indications
• The 150 mg capsule strength is for maintenance therapy only and should not be used to initiate treatment 4
• Avoid abrupt discontinuation after prolonged use; taper over 10-14 days to prevent withdrawal symptoms 4

Monitoring:

• Drowsiness is the most common side effect and typically diminishes with continued therapy 4
• Watch for anticholinergic effects (dry mouth, blurred vision, constipation, urinary retention) 4
• Monitor for cardiovascular effects including hypotension and tachycardia 4
• In elderly patients, be particularly vigilant for confusion and oversedation 4

Contraindications and Cautions:

• Avoid in patients with compromised respiratory function, hepatic/cardiac failure 4
• Use extreme caution in elderly or debilitated patients 4
• Not recommended during pregnancy or nursing 4